Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
7 studies found for:    20728210 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Recruiting Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
Conditions: Gastric Cancer;   Dual or Multiple Tumor Tissue Paraffin Blocks
Interventions: Other: Dual or Multiple Paraffin Blocks;   Other: One Paraffin Blocks
2 Completed Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer
Conditions: Stomach Neoplasms;   Neoplasms Metastasis;   ERBB2 Gene Amplification
Interventions: Drug: Trastuzumab;   Drug: Docetaxel;   Drug: Capecitabine
3 Completed
Has Results
ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
Condition: Gastric Cancer
Interventions: Drug: Trastuzumab;   Drug: Fluorouracil;   Drug: Cisplatin;   Drug: Capecitabine
4 Recruiting Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis
Condition: Stomach Neoplasm
Interventions: Procedure: Cytoreductive surgery;   Procedure: Hyperthermic Intraperitoneal Chemotherapy;   Drug: Fluoropyrimidine;   Drug: Cisplatin
5 Completed Trastuzumab Based Therapy in HER2 Positive AGC
Condition: Gastric Adenocarcinoma
Intervention: Drug: H+CT
6 Recruiting T- XELOX in HER2-positive Stage III Gastric Cancer After D2 Gastrectomy
Condition: Gastric Cancer
Interventions: Drug: Trastuzumab;   Drug: Capecitabine;   Drug: Oxaliplatin
7 Active, not recruiting Trastuzumab in Combination With Capecitabine and Oxaliplatin(XELOX) in Patients With Advanced Gastric Cancer(AGC)
Conditions: Metastatic or Recurrent Gastric Adenocarcinoma;   Her-2 Positive Gastric Cancer
Intervention: Drug: Herceptin+XELOX

Study has passed its completion date and status has not been verified in more than two years.